SRR1120755
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR615020 | GTEX | — | 0.955 |
| 2 | SRR1335047 | GTEX | — | 0.948 |
| 3 | SRR1467590 | GTEX | — | 0.946 |
| 4 | SRR602131 | GTEX | — | 0.941 |
| 5 | SRR1310623 | GTEX | — | 0.941 |
| 6 | SRR1368964 | GTEX | — | 0.940 |
| 7 | SRR1370173 | GTEX | — | 0.935 |
| 8 | SRR1315994 | GTEX | — | 0.931 |
| 9 | SRR1500800 | GTEX | — | 0.928 |
| 10 | SRR1475675 | GTEX | — | 0.926 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.432 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.422 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.408 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.382 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.380 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.309 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.297 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.268 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.258 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.254 | Idelalisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.205 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.205 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.187 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.161 | Idelalisib | — uncovered |
| COAGULATION | 0.154 | Binimetinib | — uncovered |
| MYOGENESIS | 0.151 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.077 | Idelalisib | — uncovered |